Literature DB >> 1967472

Ifosfamide pharmacokinetics and neurotoxicity.

L D Lewis, C A Meanwell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1967472     DOI： 10.1016/0140-6736(90)90054-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity.

Authors:  C Sood; P J O'Brien
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 7.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 8.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

9.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis.

Authors:  Sheron Latcha; Robert G Maki; Gary K Schwartz; Carlos D Flombaum
Journal:  Sarcoma       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.